|  
               
              Home: 
              Web Guide 1: Editor 
            Welcome to Colorectal Cancer Update 
             In recent years, treatment options for both primary and metastatic 
              colorectal cancer have improved with the availability of a number 
              of new, effective chemotherapeutic agents and combinations. The 
              future looks even brighter, as many more novel therapies and regimens 
              fill the pipeline. 
             This new series will provide practicing oncologists access to 
              the latest developments in clinical research. Utilizing an educational 
              model developed over the last 14 years in breast cancer, Colorectal 
              Cancer Update focuses on in-depth interviews with investigators 
              specializing in colorectal cancer clinical research. The perspectives, 
              opinions and experiences of these research leaders allow busy, practicing 
              oncologists to take away practical strategies that can be utilized 
              in daily patient care. 
             As in our breast cancer series, this audio program is supplemented 
              by a website  ColorectalCancerUpdate.com  which contains 
              full transcripts from the interviews and related links to journal 
              articles, abstracts and protocols. Colorectal cancer is a disease 
              with many more therapeutic options than even five years ago. Our 
              goal is to provide valuable research information and viewpoints 
              that can be applied to clinical decision-making for the thousands 
              of men and women with this disease. We look forward to many more 
              issues. 
             Neil Love, MD 
              Editor 
            
               
                | Select Agents in Phase II/III Colorectal Clinical 
                  Trials in the NCIs PDQ data base | 
               
               
                Avastin® 
                 | 
                 (bevacizumab) | 
               
               
                BiCNU® 
                 | 
                 (carmustine) | 
               
               
                | BMS-247550 | 
                (investigational epothilone B analog) | 
               
               
                | Camptosar®  | 
                (irinotecan, CPT-11) | 
               
               
                | Eloxatine®  | 
                (oxaliplatin) | 
               
               
                | Erbitux®  | 
                (cetuximab, IMC-C225) | 
               
               
                | Ergamisol®  | 
                (levamisole) | 
               
               
                | Herceptin®  | 
                (trastuzumab) | 
               
               
                | Iressa®  | 
                (ZD 1839) | 
               
               
                | Panorex® | 
                (edrecolomab) | 
               
               
                | Rubivive® | 
                 (rubitecan, RFS 2000) | 
               
               
                | Taxol® | 
                 (paclitaxel) | 
               
               
                | Thalomid® | 
                 (thalidomide) | 
               
               
                | Xeloda® | 
                 (capecitabine) | 
               
             
              
            
              
             |